In January 2024, LEQEMBI was approved for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as ...
We address this question through investigation of the progressive nature of neurodegeneration in both invertebrate and ...
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
DRINKING a 17p beverage is one of the many ways you can slow your brain ageing, according to a new study. It’s no secret that ...
AZoLifeSciences on MSN
Protein Networks Expose New Therapeutic Targets for Alzheimer's
A recent study conducted by the Icahn School of Medicine at Mount Sinai provides one of the most thorough insights to date ...
A simple urine test could reveal your risk of developing dementia decades before symptoms appear, a new study shows. For the ...
This award strongly validates our approach to Alzheimer’s disease,” said Dr. Carmela Abraham, Chief Science Officer. “With NIH support, we are one step closer to helping patients suffering from this ...
On November 4, 2024, Karolinska Institutet (KI) hosted the symposium "Beyond Amyloid and Tau: The Importance of ...
A new study led by the Icahn School of Medicine at Mount Sinai offers one of the most comprehensive views yet of how brain ...
Alzheimer’s disease and related dementias (ADRD) pose an escalating global public health challenge, with increasing demand for earlier, more accurate ...
In Alzheimer’s disease, Hameroff says, scientists don’t know whether the microtubules disintegrate and release the tau or whether the tau falls off because of a malfunction that weakens the bond. The ...
A new study led by the Icahn School of Medicine at Mount Sinai offers one of the most comprehensive views yet of how brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback